s
s
s
Develop highly selective and sensitive PK and ADA assays for the immune checkpoint inhibitor drug ipilimumab (Yervoy) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Ipilimumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Ipilimumab Inhibitory Type 1 |
HCA330 |
AbD34433 |
Fab-FSx21 |
0.3 |
PK bridging ELISA |
|
HCA329 |
AbD34429ia |
Human IgG1 HRP |
1 |
PK bridging ELISA ADA control |
||
HCA327 |
AbD34283ia |
Human IgG1 |
16 |
ADA control |
||
HCA328 |
AbD34428ia |
Human IgG1 |
0.3 |
ADA control |
||
Ipilimumab-CTLA-4 Complex Specific |
HCA331 |
AbD34294 |
Fab-FSx21 |
252 |
PK ELISA antigen capture format |
|
TZA001 |
AbD34294ad |
Fab-F-Spy2-H |
252 |
PK ELISA antigen capture format |
||
TZA001P |
AbD34294pap |
Fab2-FH-X22-HRP |
252 |
PK ELISA antigen capture format |
*Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody with DYKDDDDK (F) and StrepX-StrepX (Sx2) tags
2 Monovalent Fab antibody with DYKDDDDK (F), SpyTag version 2 (Spy2) and His6 (H) tags
3 Bivalent Fab antibody generated by coupling TZA001 (AbD34294ad) with HRP conjugated BiSpyCatcher2 (TZC002)
Type 1 anti-ipilimumab antibodies inhibit the binding of the drug ipilimumab to its target, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in three different affinities, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The Type 3 antibody specifically recognizes the drug-target complex, detecting ipilimumab only when it is bound to CTLA-4. It is suitable as a detection antibody in a PK antigen capture assay, as an alternative assay format to the bridging ELISA. Clone AbD34294 is available in three formats:
Fig. 1. Ipilimumab PK bridging ELISA using antibodies HCA330 and HCA329P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Ipilimumab PK antigen capture ELISA using antibody TZA001P.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, Fab2 antibody (purple), and BiSpyCatcher2 (gray) labeled with HRP (orange).
Fig. 3. Ipilimumab PK antigen capture ELISA using antibody HCA331.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), anti-tag detection antibody labeled with HRP (gray).
Fig. 4. Ipilimumab ADA bridging ELISA using antibody HCA327, HCA328, or HCA329.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.